Cargando…

Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance

ABSTRACT: Replacement of growth hormone (GH) in patients suffering from GH deficiency (GHD) offers clinical benefits on body composition, exercise capacity, and skeletal integrity. However, GH replacement therapy (GHRT) is also associated with insulin resistance, but the mechanisms are incompletely...

Descripción completa

Detalles Bibliográficos
Autores principales: Galimov, Artur, Hartung, Angelika, Trepp, Roman, Mader, Alexander, Flück, Martin, Linke, Axel, Blüher, Matthias, Christ, Emanuel, Krützfeldt, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661224/
https://www.ncbi.nlm.nih.gov/pubmed/26199111
http://dx.doi.org/10.1007/s00109-015-1322-y
_version_ 1782402943364890624
author Galimov, Artur
Hartung, Angelika
Trepp, Roman
Mader, Alexander
Flück, Martin
Linke, Axel
Blüher, Matthias
Christ, Emanuel
Krützfeldt, Jan
author_facet Galimov, Artur
Hartung, Angelika
Trepp, Roman
Mader, Alexander
Flück, Martin
Linke, Axel
Blüher, Matthias
Christ, Emanuel
Krützfeldt, Jan
author_sort Galimov, Artur
collection PubMed
description ABSTRACT: Replacement of growth hormone (GH) in patients suffering from GH deficiency (GHD) offers clinical benefits on body composition, exercise capacity, and skeletal integrity. However, GH replacement therapy (GHRT) is also associated with insulin resistance, but the mechanisms are incompletely understood. We demonstrate that in GH-deficient mice (growth hormone-releasing hormone receptor (Ghrhr)(lit/lit)), insulin resistance after GHRT involves the upregulation of the extracellular matrix (ECM) and the downregulation of microRNA miR-29a in skeletal muscle. Based on RNA deep sequencing of skeletal muscle from GH-treated Ghrhr(lit/lit) mice, we identified several upregulated genes as predicted miR-29a targets that are negative regulators of insulin signaling or profibrotic/proinflammatory components of the ECM. Using gain- and loss-of-function studies, five of these genes were confirmed as endogenous targets of miR-29a in human myotubes (PTEN, COL3A1, FSTL1, SERPINH1, SPARC). In addition, in human myotubes, IGF1, but not GH, downregulated miR-29a expression and upregulated COL3A1. These results were confirmed in a group of GH-deficient patients after 4 months of GHRT. Serum IGF1 increased, skeletal muscle miR-29a decreased, and miR-29a targets were upregulated in patients with a reduced insulin response (homeostatic model assessment of insulin resistance (HOMA-IR)) after GHRT. We conclude that miR-29a could contribute to the metabolic response of muscle tissue to GHRT by regulating ECM components and PTEN. miR-29a and its targets might be valuable biomarkers for muscle metabolism following GH replacement. KEY MESSAGES: GHRT most significantly affects the ECM cluster in skeletal muscle from mice. GHRT downregulates miR-29a and upregulates miR-29a targets in skeletal muscle from mice. PTEN, COL3A1, FSTL1, SERPINH1, and SPARC are endogenous miR-29a targets in human myotubes. IGF1 decreases miR-29a levels in human myotubes. miR-29a and its targets are regulated during GHRT in skeletal muscle from humans. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1322-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4661224
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-46612242015-12-04 Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance Galimov, Artur Hartung, Angelika Trepp, Roman Mader, Alexander Flück, Martin Linke, Axel Blüher, Matthias Christ, Emanuel Krützfeldt, Jan J Mol Med (Berl) Original Article ABSTRACT: Replacement of growth hormone (GH) in patients suffering from GH deficiency (GHD) offers clinical benefits on body composition, exercise capacity, and skeletal integrity. However, GH replacement therapy (GHRT) is also associated with insulin resistance, but the mechanisms are incompletely understood. We demonstrate that in GH-deficient mice (growth hormone-releasing hormone receptor (Ghrhr)(lit/lit)), insulin resistance after GHRT involves the upregulation of the extracellular matrix (ECM) and the downregulation of microRNA miR-29a in skeletal muscle. Based on RNA deep sequencing of skeletal muscle from GH-treated Ghrhr(lit/lit) mice, we identified several upregulated genes as predicted miR-29a targets that are negative regulators of insulin signaling or profibrotic/proinflammatory components of the ECM. Using gain- and loss-of-function studies, five of these genes were confirmed as endogenous targets of miR-29a in human myotubes (PTEN, COL3A1, FSTL1, SERPINH1, SPARC). In addition, in human myotubes, IGF1, but not GH, downregulated miR-29a expression and upregulated COL3A1. These results were confirmed in a group of GH-deficient patients after 4 months of GHRT. Serum IGF1 increased, skeletal muscle miR-29a decreased, and miR-29a targets were upregulated in patients with a reduced insulin response (homeostatic model assessment of insulin resistance (HOMA-IR)) after GHRT. We conclude that miR-29a could contribute to the metabolic response of muscle tissue to GHRT by regulating ECM components and PTEN. miR-29a and its targets might be valuable biomarkers for muscle metabolism following GH replacement. KEY MESSAGES: GHRT most significantly affects the ECM cluster in skeletal muscle from mice. GHRT downregulates miR-29a and upregulates miR-29a targets in skeletal muscle from mice. PTEN, COL3A1, FSTL1, SERPINH1, and SPARC are endogenous miR-29a targets in human myotubes. IGF1 decreases miR-29a levels in human myotubes. miR-29a and its targets are regulated during GHRT in skeletal muscle from humans. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-015-1322-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-07-23 2015 /pmc/articles/PMC4661224/ /pubmed/26199111 http://dx.doi.org/10.1007/s00109-015-1322-y Text en © Springer-Verlag Berlin Heidelberg 2015
spellingShingle Original Article
Galimov, Artur
Hartung, Angelika
Trepp, Roman
Mader, Alexander
Flück, Martin
Linke, Axel
Blüher, Matthias
Christ, Emanuel
Krützfeldt, Jan
Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance
title Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance
title_full Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance
title_fullStr Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance
title_full_unstemmed Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance
title_short Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance
title_sort growth hormone replacement therapy regulates microrna-29a and targets involved in insulin resistance
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661224/
https://www.ncbi.nlm.nih.gov/pubmed/26199111
http://dx.doi.org/10.1007/s00109-015-1322-y
work_keys_str_mv AT galimovartur growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT hartungangelika growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT trepproman growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT maderalexander growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT fluckmartin growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT linkeaxel growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT bluhermatthias growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT christemanuel growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance
AT krutzfeldtjan growthhormonereplacementtherapyregulatesmicrorna29aandtargetsinvolvedininsulinresistance